Device Trial Radar · NCT03390504
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
629
Actual
Start
Mar 23, 2018
Primary completion
Apr 15, 2024
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
Conditions
- Urothelial Cancer
Interventions
ErdafitinibDrug
Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
VinflunineDrug
Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.
DocetaxelDrug
Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.
PembrolizumabDrug
Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)Device
FGFRi CTA will be used to determine molecular eligibility.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)
Locations
345 sites in 27 countries. Site status is shown where the registry gives one.
Alaska Urological Institute dba Alaska Clinical Research Center
Anchorage, Alaska
University of Calif Davis Medical Center
Sacramento, California
St. Helena Hospital - Martin-O'Neil Cancer Center
St. Helena, California
342 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.